TX-MAVENIR
11.3.2021 15:02:11 CET | Business Wire | Press release
Mavenir, the industry’s only end-to-end cloud-native Network Software Provider and a leader in accelerating software network transformation for communications service providers (CSPs), announced today its extended Artificial Intelligence (AI) and Analytics portfolio to enable closed-loop automation and drive digital transformation.
AI and machine learning (ML) in mobile network infrastructure is expected to lower costs by automating functions that typically require human interaction and to speed new revenue generating service offerings, becoming increasingly important as edge, open radio access networks (Open RAN), and 5G cores get deployed.
Mavenir’s AI and Analytics portfolio includes solutions designed to analyze and derive inferences from vast amounts of unstructured data to automate networks, achieve cost savings, and build out 5G use cases. Many Industry 4.0 use cases such as Intelligent Video Analytics and AR/VR are enabled by 5G that require AI-driven inferences at the edge. Mavenir’s portfolio includes these AI-enabled applications for Network Automation, Intelligent Operations, EdgeAI, and Network Security.
1)
|
Network Automation: Mavenir’s RAN Intelligent Controller (RIC) and Network Data Analytics Function (NWDAF) follow the specifications introduced by the O-RAN Alliance and 3GPP and operate as the heart of a network automation vision. The RIC and NWDAF enable the network to dynamically adapt to traffic conditions using machine learning (ML)-based algorithms and applications that can be deployed in any network in a multi-vendor environment. Mavenir’s containerized RIC and NWDAF product capabilities include: |
|
|
2)
|
Intelligent Operations: By automating network operational processes with AI and analytics solutions, operators should be able to substantially reduce the cost and time from traditional, more labor-intensive methods such as drive testing, log inspection, troubleshooting, and manual calibration. With AI-based prediction engines, operators can achieve intelligent capacity planning and reduce the possibility of large-scale network outages. With anomaly detection capability, operators can uncover underlying network faults that are not easily visible. This AI-driven Operations (AIOps) solution using ML techniques plays a key role in reducing operating expenses and gives operators complete control over their networks. |
|
|
3)
|
5G EdgeAI : Mavenir’s 5G EdgeAI solution includes Intelligent Video Analytics that can support myriad of use cases from facial recognition to anomaly detection for smart city and industry 4.0 use cases. Next generation of AR/VR applications are accelerated and enhanced by this edge platform. Large number of sensor data gets analyzed and actions are taken in a matter of milliseconds by the edge Industrial Internet of Things (IIoT) analytics application. |
|
|
|
“AI is the key driver for Industry 4.0, providing real-time insights & control of industrial processes. Low latency, high density of 5G are also enablers, so in essence, the combination of 5G and AI = Industry 4.0,” said Kuntal Chowdhury, SVP and GM, Mavenir AI and Analytics Business Unit. “While Mavenir’s AI and Analytics solutions are now available as standalone solutions, we have been offering intelligent insights as integrated solutions to Tier 1 customers around the world for years. Currently over 200 systems are deployed in more than 80 customer networks and our solutions process and analyze billions of records per day, offering real-time/near-real-time insights to optimize network performance with little to no human intervention.” |
|
|
4)
|
Network security: As new vulnerabilities arise, Mavenir’s Fraud Management and Security Suite protect the network in real-time with predictive analytics and ML. The Real-Time Fraud Management and Security analytics is leveraging unique ML algorithms and a specifically designed framework suited to manage the volume, velocity, and variety of structured and unstructured data over wireless networks. |
|
|
|
“Mavenir Security and Anti-Fraud Solutions based on AI/ML are taking care of on-going revenue savings at Telefónica Argentina,” says Diego Quevedo, Core Network Solution Design Lead, Telefónica Argentina. “We are in close cooperation with Mavenir to ensure the up-to-date protection of our network.” |
|
|
|
“Mavenir’s approach of applying Real-Time Machine Learning technology to protect key operator services and revenue has been highly valued by customers,” said Ilia Abramov, VP and GM, Mavenir Security BU. “New threats raised in the recent years and increasing attack vectors on Mobile Network Services have been successfully detected and blocked though our installed base. The increased level of trust of our AI/ML technology has been confirmed with substantial growth in additional network implementations in the last year.” |
“Leveraging our deep AI/ML knowledge and advanced capabilities enables Communications Service Providers to optimize, automate and advance their mobile networks for the future of 5G,” said BG Kumar, President, Mavenir’s Communications Services Business Group. “Network automation and service protection driven by AI/ML are core capabilities of Mavenir and one of the highest priorities of our customers, and we are proud to provide this solution set to enable them to realize their vision.”
Mavenir’s AI/ML and Analytics solutions and Fraud/Security solutions are deployed at multiple Tier 1 operator networks across North America, EMEA, and APAC regions. Additionally, Mavenir is dedicated to continuous AI/ML innovation through the R&D Center of Excellence in Brno, Czech Republic, and R&D in Richardson TX and Bangalore, India.
About Mavenir:
Mavenir is the industry's only end-to-end, cloud-native Network Software and Solutions/Systems Integration Provider, focused on accelerating software network transformation. Mavenir offers a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack for communications service providers and enterprises. From 5G application layers (VoLTE, Messaging) to Packet Core and RAN, Security, Edge Analytics and AI, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users.
Leveraging innovations in Mobile Core with IMS (VoLTE, VoWiFi, Advanced Messaging/RCS), and Packet Core (vEPC, 5G Core) as well as Radio Access/Edge (OpenRAN), Private Networks, as well as Mobile Services and Applications such as Digital Enablement. Mavenir accelerates digital network transformation for more than 250+ CSP customers in over 120 countries, which serve over 50% of the world’s subscribers. www.mavenir.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005034/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
